According to an international collaborative phase III study called “Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48)” for patients with atrial fibrillation and a moderate to a high risk of cerebral infarct, the incidences of gastrointestinal hemorrhage were 1.23% for warfarin, 1.51% for high-dose edoxaban, and 0.87% for low-dose edoxaban [4]. This evidence concerns the gene F10 and cerebral infarction.